Alzamend Neuro Inc Ordinary Shares ALZN 深 滬
交易中 08-06 10:08:11 美东时间
2.4073
+0.027
+1.15%
華盛通- 最 高2.44
- 今 開2.41
- 成交量 2.72万股
- 最 低 2.3287
- 昨 收 2.38
- 總市值 192.82万
- 52周最高 135.54
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.06
- 委 比 0.00%
- 總股本 80.10万
- 歷史最高 45292.50
- 量 比 2.82
- 振 幅 4.68%
- 歷史最低 2.3287
- 每 手 1
- 風險率 6.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alzamend Neuro Increases Common Stock Through Conversion
Alzamend Neuro ( ($ALZN) ) has issued an announcement. Between July 23, 2025, a...
08-02 05:06
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Alzamend Neuro, Inc. will present a study at MHSRS 2025 comparing lithium brain-to-plasma exposure in PTSD patients using AL001 and lithium carbonate. AL001 is a novel lithium-delivery system designed to improve brain targeting and reduce systemic side effects. The study aims to establish optimal dosing for PTSD and other conditions. Alzamend is advancing clinical trials for AL001 to treat Alzheimer's, bipolar disorder, major depressive disorder,...
07-28 12:00
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro reported financial results for the year ended April 30, 2025, highlighting $10.4 million in net cash from financing activities and $4.0 million in stockholder equity, including $3.9 million in cash. In May 2025, the company dosed the first healthy patient in its AL001 "Lithium in Brain" studies at Massachusetts General Hospital. Alzamend also completed its $5 million private placement in June 2025, months ahead of schedule, strengt...
07-23 12:00
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Alzamend Neuro, Inc. has completed a $5 million private placement months ahead of schedule, with proceeds supporting five Phase II clinical trials for AL001 "Lithium in Brain" Studies at Massachusetts General Hospital. The trials target Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD, with the first study expected to report results by year-end. CEO Stephan Jackman expressed gratitude to the investor for accelerating the program...
06-16 12:00
Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update
Alzamend Neuro stock rocketed on Thursday after the company announced an update...
05-29 21:25
Alzamend Neuro shares are trading higher after the company dosed the first patient in its Phase II clinical trial of AL001.
Alzamend Neuro shares are trading higher after the company dosed the first pati...
05-29 20:05
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Alzamend Neuro, Inc. has dosed the first patient in its Phase II clinical trial of AL001, a novel lithium-delivery system, in healthy human subjects. This study, conducted at Massachusetts General Hospital, aims to compare AL001's effectiveness in delivering lithium to the brain versus traditional lithium salts, potentially reducing systemic side effects and eliminating the need for therapeutic drug monitoring (TDM). AL001 has shown promise in pr...
05-29 12:00
Alzamend Neuro Enrolls First Patient Of First Phase II Clinical Study Of AL001, In Healthy Human Subjects; Topline Data Expected By Year End
Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy
05-19 20:02
EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91%
Intelligent Bio Solutions reported a Q3 loss of 44 cents per share with a 20% revenue rise from Q2 and 91% year-over-year gross profit growth.
05-13 20:00
Healthcare stocks that could be poised for a rebound
Health care (NYSEARCA:XLV) is the most oversold global sector, according to BofA. The sector was down 6.3% from its 200-day moving average in U.S. dollar terms, followed by energy (XLE) and biotechnol...
05-10 00:31
